Loading...
Loading...
In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer resumed coverage on BioMarin Pharmaceuticals
BMRN with an Overweight rating and set a price target of $87.00.
In the report, Piper Jaffray says "We are resuming coverage of BMRN with an Overweight rating and $87 PT. The company's attractive pipeline continues to march forward as Vimizim is expected to launch in 2014 (PDUFA Feb 28th). PEG-PAL (for PKU), BMN-763 (for germline BRCA breast cancer) and BMN-701(for Pompe) are all in or entering Phase III and are steadily making their way into consensus estimates. But one product stands out to us still as conceptually de-risked and likely to become clinically de-risked by the end of 2014, namely BMN-111 for achondroplastic dwarfism. We believe the existing data from preclinical models with bridging human genetic observations make this program highly likely to succeed. We believe this program can add $1B of high-margin revenue to BMRN's portfolio by addressing an important unmet need."
BioMarin closed on Tuesday at $70.53.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in